Logo

Roche Reports Results of MabThera/Rituxan (rituximab) in P-III PEMPHIX Study for Pemphigus Vulgaris

Share this

Roche Reports Results of MabThera/Rituxan (rituximab) in P-III PEMPHIX Study for Pemphigus Vulgaris

Shots:

  • The P-III PEMPHIX study involves assessing of MabThera/Rituxan vs Mycophenolate Mofetil (MMF) in patients with moderate to severe active PV- requiring 60-120 mg/day oral prednisone (or equivalent) for 52wks.
  • The P-III PEMPHIX study results: met its 1EPs i.e- superior to MMF in achieving sustained CR without using steroids for 16+ consecutive wks. (40.3% vs 9.5%); met its 2EPs i.e- low cumulative oral corticosteroid dose- fewer flares- greater sustained CR- the lesser likelihood of flare- improvement in DLQI
  • MabThera/Rituxan targets CD20- indicated to treat GPA & MPA in combination with glucocorticoids in adults & children & used to treat RA in combination with MTX and has received FDA & EMA’s approval for PV in Jun’18 & Mar’19 respectively

Click here to­ read full press release/ article 

Ref: Roche | Image: Roche


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions